We are live on ! Find out more
MLYS icon

Mineralys Therapeutics
MLYS

77 hedge funds and large institutions have $252M invested in Mineralys Therapeutics in 2023 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 28 increasing their positions, 11 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

155% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 11

69% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 13

13% more funds holding

Funds holding: 68 → 77 (+9)

3.24% more ownership

Funds ownership: 61.64% → 64.89% (+3.2%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

41% less capital invested

Capital invested by funds: $429M → $252M (-$177M)

Holders
77
Holders Change
+9
Holders Change %
+13.24%
% of All Funds
1.22%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
22
Increased
28
Reduced
11
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
B
Braidwell
Connecticut
+$19.2M
2
CA
CHI Advisors
New York
+$7.41M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$5.97M
4
Millennium Management
Millennium Management
New York
+$4.75M
5
LCM
Laurion Capital Management
New York
+$3.78M

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$14.3M
2
APM
Avidity Partners Management
Texas
-$13.1M
3
GPP
Great Point Partners
Connecticut
-$9.31M
4
Jennison Associates
Jennison Associates
New York
-$6.06M
5
ASP
Adams Street Partners
Illinois
-$1.53M
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$1.28M +$1.1M +84,507 +168%
Ensign Peak Advisors
27
Ensign Peak Advisors
Utah
$1.19M – – –
Northern Trust
28
Northern Trust
Illinois
$1.06M -$7.81K -599 -0.5%
Charles Schwab
29
Charles Schwab
California
$1.01M +$140K +10,715 +11%
Renaissance Technologies
30
Renaissance Technologies
New York
$910K +$1.25M +95,690 New
Jane Street
31
Jane Street
New York
$409K +$561K +43,057 New
RJFSA
32
Raymond James Financial Services Advisors
Florida
$386K +$529K +40,578 New
Bank of New York Mellon
33
Bank of New York Mellon
New York
$384K +$2.83K +217 +0.5%
Alyeska Investment Group
34
Alyeska Investment Group
Illinois
$357K – – –
Two Sigma Investments
35
Two Sigma Investments
New York
$343K +$471K +36,103 New
JF
36
Jump Financial
Illinois
$311K +$426K +32,700 New
AA
37
ALPS Advisors
Colorado
$287K +$1.53K +117 +0.4%
OQS
38
Occudo Quantitative Strategies
Florida
$214K +$293K +22,489 New
Federated Hermes
39
Federated Hermes
Pennsylvania
$212K +$22.2K +1,700 +8%
N
40
Nuveen
North Carolina
$182K – – –
XT
41
XTX Topco
Cayman Islands
$178K +$243K +18,670 New
Citadel Advisors
42
Citadel Advisors
Florida
$177K +$243K +18,616 New
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
$163K +$29.7K +2,279 +15%
AllianceBernstein
44
AllianceBernstein
Tennessee
$151K +$62.3K +4,780 +43%
Walleye Capital
45
Walleye Capital
New York
$145K +$199K +15,255 New
PP
46
PDT Partners
New York
$132K +$181K +13,912 New
Bank of America
47
Bank of America
North Carolina
$126K +$13.4K +1,030 +8%
LBA
48
Letko, Brosseau & Associates
Quebec, Canada
$108K – – –
Russell Investments Group
49
Russell Investments Group
United Kingdom
$96.8K +$133K +10,180 New
TRCT
50
Tower Research Capital (TRC)
New York
$95.7K +$127K +9,718 +2,842%
1
2
3 4

MLYS Hedge Fund Activity: Q3 2023 in Review

77 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Mineralys Therapeutics (MLYS) for Q3 2023, worth a combined $252M — down 41% from $429M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new MLYS positions and 13 closed out — a net gain of 9 holders — while 28 added to existing stakes and 11 trimmed.

The largest buyer was Braidwell, adding an estimated $19.2M. The largest seller was Deerfield Management, exiting entirely with an estimated $14.3M sold.

  • 77 institutional investors held Mineralys Therapeutics (MLYS) as of Q3 2023, up from 68 in Q2 2023.
  • Funds reported $252M of Mineralys Therapeutics stock for Q3 2023, down 41% quarter-over-quarter.
  • 22 funds opened new Mineralys Therapeutics positions in Q3 2023 and 13 closed out, a net change of +9 holders.
  • The largest Mineralys Therapeutics buyer in Q3 2023 was Braidwell, an estimated $19.2M added.
  • The largest Mineralys Therapeutics seller in Q3 2023 was Deerfield Management, an estimated $14.3M sold.

Based on aggregated 13F filings for Q3 2023.